Scholarlink

Introduction <p>Treatment persistence is critical to obtaining full therapeutic benefit and can indicate favorable outcomes. This study examined real-world persistence with ocrelizumab (OCR) versus other disease-modifying therapies (DMTs) and its association with outcomes in relapsing–remitting multiple sclerosis (RRMS) using German NeuroTransData (NTD) registry data.</p> Methods <p>This retrospective cohort analysis included outpatients with RRMS who initiated a DMT between January 2014 and April 2022. DMT initiation date was defined as the index date. DMTs were grouped into OCR, injectable, oral, oral for highly active disease (oral HA), and other intravenous (IV) therapies. Persistence, based on having continuous records of a DMT for 2&#xa0;years from index date, was evaluated within each group. Association between persistence and the risk of relapse, 3-months confirmed disability progression (3mCDP), and sick leave were assessed.</p> Results <p>Overall, 3907 patients with RRMS were included. OCR users had the highest persistence at 2&#xa0;years (93%), then oral HA (78%), oral (67%), natalizumab (67%), and injectable therapies (55%). Compared with OCR users, patients initiating injectable (hazard ratio [HR] 8.51, 95% confidence interval [CI] 4.03–17.90), oral (HR 5.92, 95%&#xa0;CI 2.81–12.50), oral HA (HR 3.49, 95%&#xa0;CI 1.63–7.48) therapies, and natalizumab (HR 5.47, 95%&#xa0;CI 2.47–12.10) were more likely to discontinue. Adverse events (32.47%), lack of efficacy (21.17%), and patient-driven factors (19.73%) were the main reasons for discontinuation. Compared with persisters, non-persisters were associated with higher risks of relapse activity (rate ratio: 2.18, 95%&#xa0;CI 1.98–2.39), 3mCDP (rate ratio 1.52, 95%&#xa0;CI 1.28–1.77), and sick leave (rate ratio 1.71, 95%&#xa0;CI 1.49–1.98).</p> Conclusion <p>In a German real-world setting, patients initiating OCR achieved higher rates of persistence over 2&#xa0;years compared with those on other DMTs. High persistence was associated with lower risk of clinical disease activity, disease progression, and sick leave.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月2日

查看全文
  • Stefan Braune,
  • Petra Dirks,
  • Seya Colloud,
  • Qing Wang,
  • Evan Davies,
  • Yanic Heer,
  • Mel Zürcher,
  • Diana Sun,
  • Arnfin Bergmann

摘要

Introduction

Treatment persistence is critical to obtaining full therapeutic benefit and can indicate favorable outcomes. This study examined real-world persistence with ocrelizumab (OCR) versus other disease-modifying therapies (DMTs) and its association with outcomes in relapsing–remitting multiple sclerosis (RRMS) using German NeuroTransData (NTD) registry data.

Methods

This retrospective cohort analysis included outpatients with RRMS who initiated a DMT between January 2014 and April 2022. DMT initiation date was defined as the index date. DMTs were grouped into OCR, injectable, oral, oral for highly active disease (oral HA), and other intravenous (IV) therapies. Persistence, based on having continuous records of a DMT for 2 years from index date, was evaluated within each group. Association between persistence and the risk of relapse, 3-months confirmed disability progression (3mCDP), and sick leave were assessed.

Results

Overall, 3907 patients with RRMS were included. OCR users had the highest persistence at 2 years (93%), then oral HA (78%), oral (67%), natalizumab (67%), and injectable therapies (55%). Compared with OCR users, patients initiating injectable (hazard ratio [HR] 8.51, 95% confidence interval [CI] 4.03–17.90), oral (HR 5.92, 95% CI 2.81–12.50), oral HA (HR 3.49, 95% CI 1.63–7.48) therapies, and natalizumab (HR 5.47, 95% CI 2.47–12.10) were more likely to discontinue. Adverse events (32.47%), lack of efficacy (21.17%), and patient-driven factors (19.73%) were the main reasons for discontinuation. Compared with persisters, non-persisters were associated with higher risks of relapse activity (rate ratio: 2.18, 95% CI 1.98–2.39), 3mCDP (rate ratio 1.52, 95% CI 1.28–1.77), and sick leave (rate ratio 1.71, 95% CI 1.49–1.98).

Conclusion

In a German real-world setting, patients initiating OCR achieved higher rates of persistence over 2 years compared with those on other DMTs. High persistence was associated with lower risk of clinical disease activity, disease progression, and sick leave.